|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Portal vein thrombosis and arterioportal shunts:Effects on tumor response after chemoembolization of hepatocellular carcinoma显示文摘AIM: To evaluate the effect of portal vein thrombosis and arterioportal shunts on local tumor response in advanced cases of unresectable hepatocellular carcinoma treated by transarterial chemoembolization. METHODS: A retrospective study included 39 patients (mean age: 66.4 years, range: 45-79 years, SD: 7) with unresectable hepatocellular carcinoma (HCC) who were treated with repetitive transarterial chemoembolization (TACE) in the period between March 2006 and October 2009. The effect of portal vein thrombosis (PVT) (in 19 out of 39 patients), the presence of arterioportal shunt (APS) (in 7 out of 39), the underlying liver pathology,Child-Pugh score, initial tumor volume, number of tumors and tumor margin definition on imaging were correlated with the local tumor response after TACE. The initial and end therapy local tumor responses were evaluated according to the response evaluation criteria in solid tumors (RECIST) and magnetic resonance imaging volumetric measurements. RESULTS: The treatment protocols were well tolerated by all patients with no major complications. Local tumor response for all patients according to RECIST criteria were partial response in one patient (2.6%), stable disease in 34 patients (87.1%), and progressive disease in 4 patients (10.2%). The MR volumetric measurements showed that the PVT, APS, underlying liver pathology and tumor margin definition were statistically significant prognostic factors for the local tumor response (P = 0.018, P = 0.008, P = 0.034 and P = 0.001, respectively). The overall 6-, 12- and 18-mo survival rates from the initial TACE were 79.5%, 37.5% and 21%, respectively. CONCLUSION: TACE may be exploited safely for palliative tumor control in patients with advanced unresectable HCC; however, tumor response is significantly affected by the presence or absence of PVT and APS. | Thomas J Vogl Nour-Eldin Nour-Eldin Sally Emad-Eldin Nagy NN Naguib Joerg Trojan Hans Ackermann Omar Abdelaziz | 2011 | World Journal of Gastroenterology2011，17，10： | 20 |
| 2 | Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction显示文摘AIM: To evaluate the safety and technical success of endoscopic radiofrequency ablation(RFA) for palliative treatment of malignant hilar bile duct obstruction. METHODS: In this study, a recently CE and FDA-approved endoscopic RFA catheter was first tested in an ex vivo pig liver model to study the effect of electrosurgical variables on the extent of the area of induced necrosis. Subsequently, a retrospective analysis was conducted of all patients treated with endoscopic RFA for malignant biliary obstruction at our center between February 2012 and April 2013. All patients received an additional plastic stent implantation into the biliary tree following RFA. RESULTS: In the pig model, ablation time of 60-90 seconds using the bipolar soft coagulation mode at 8-10 watts with an effect of 8 was found to be the most feasible setting. Twelve patients(5 females, 7 males; mean age, 70 years) underwent 19 endoscopic RFA(range, 1-5) sessions. Deployment of RFA was successful in all patients. Systemic chemotherapy was administered in four patients. We observed biliary bleeding 4-6 wk after the intervention in three cases and two of these patients died: in one patient, spontaneous hemobilia occurred, whereas bleeding started during stent extraction in the other. In the third patient, bleeding was stopped by insertion of a non-covered self-expanding metal stent. Another three patients developed cholangitis during follow-up. Seven patients died during follow-up and median survival was 6.4 mo(95%CI: 0.05-12.7) from the time of the first RFA. CONCLUSION: Endoscopic RFA is an easy to perform and technically highly successful procedure. However, hemobilia possibly associated with RFA occurred in three of our patients. Therefore, larger prospective studies are needed to further evaluate the safety and efficacy of this promising new method. | Andrea Oliver Tal Johannes Vermehren Mireen FriedrichRust Jrg Bojunga Christoph Sarrazin Stefan Zeuzem Jrg Trojan Jrg Gerhard Albert | 2014 | World Journal of Gastrointestinal Endoscopy2014，6，1： | 18 |
| 3 | Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives显示文摘Hepatocellular carcinoma(HCC) is among the most common cancer diseases worldwide.Arterial hypervascularisation is an essential step for HCC tumorigenesis and can be targeted by transarterial chemoembolization(TACE).This interventional method is the standard treatment for patients with intermediate stage HCC,but is also applied as 'bridging' therapy for patients awaiting liver transplantation in many centers worldwide.Usually the devascularization effect induced by TACE is transient,consequently resulting in repeated cycles of TACE every 4-8 wk.Despite documented survival benefits,TACE can also induce the up-regulation of proangiogenic and growth factors,which might contribute to accelerated progression in patients with incomplete response.In 2007,sorafenib,a multi-tyrosine kinase and angiogenesis inhibitor,was approved as the first systemic treatment for advanced stage HCC.Other active targeted compounds,either inhibitors of angiogenesis and/or growth factors,are currently being investigated in numerous clinical trials.To overcome revascularisation or tumor progression under TACE treatment it seems therefore attractive to combine TACE with systemic targeted agents,which might theoretically block the effects of proangiogenic and growth factors.Over the last 12 mo,several retrospec-tive or prospective cohort studies combining TACE and sorafenib have been published.Nevertheless,robust results of the efficacy and tolerability of such combination strategies as proven by randomized,controlled trials are awaited in the next two years. | Martin-Walter Welker Joerg Trojan | 2011 | World Journal of Gastroenterology2011，17，26： | 14 |
| 4 | SEMS vs cSEMS in duodenal and small bowel obstruction:High risk of migration in the covered stent group显示文摘AIM:To compare clinical success and complications of uncovered self-expanding metal stents(SEMS)vs covered SEMS(cSEMS)in obstruction of the small bowel.METHODS:Technical success,complications and outcome of endoscopic SEMS or cSEMS placement in tumor related obstruction of the duodenum or jejunum were retrospectively assessed.The primary end points were rates of stent migration and overgrowth.Secondary end points were the effect of concomitant biliary drainage on migration rate and overall survival.The data was analyzed according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.RESULTS:Thirty-two SEMS were implanted in 20 patients.In all patients,endoscopic stent implantation was successful.Stent migration was observed in 9 of16 cSEMS(56%)in comparison to 0/16 SEMS(0%)implantations(P=0.002).Stent overgrowth did not significantly differ between the two stent types(SEMS:3/16,19%;cSEMS:2/16,13%).One cSEMS dislodged and had to be recovered from the jejunum by way of laparotomy.Time until migration between SEMS and cSEMS in patients with and without concomitant biliary stents did not significantly differ(HR=1.530,95%CI0.731-6.306;P=0.556).The mean follow-up was 57±71 d(range:1-275 d).CONCLUSION:SEMS and cSEMS placement is safe in small bowel tumor obstruction.However,cSEMS is accompanied with a high rate of migration in comparison to uncovered SEMS. | Oliver Waidmann Jrg Trojan Mireen Friedrich-Rust Christoph Sarrazin Wolf Otto Bechstein Frank Ulrich Stefan Zeuzem Jrg Gerhard Albert | 2013 | World Journal of Gastroenterology2013，19，37： | 4 |
| 5 | Protective effect of flavonoidsand tocopherol in high altitude hypoxia in the rat:comparison with ascorbic acid显示文摘 | Schreber M Trojan S | 1998 | Cesk Fysiol1998，47，： | 2 |
| 6 | Complications in Percutaneous Nephrolithotomy 显示文摘 | Maurice Stephan Michel Lutz Trojan Jens Jochen Rassweiler | 2006 | European Urology2006，，： | 2 |
| 7 | Recurrent hepatocellular carcinoma after liver transplantation – an emerging clinical challenge显示文摘 | Martin‐Walter Welker Wolf‐Otto Bechstein Stefan Zeuzem Joerg Trojan | 2012 | Transplant International2012，，2： | 2 |
| 8 | Complications in Percutaneous Nephrolithotomy <ce:link locator='eulogo1'/>显示文摘 | Maurice Stephan Michel Lutz Trojan Jens Jochen Rassweiler | 2006 | European Urology2006，，4： | 2 |
| 9 | Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma显示文摘 | Verena K?berle Bernd Kronenberger Thomas Pleli J?rg Trojan Esther Imelmann Jan Peveling-Oberhag Martin-Walter Welker Mohammed Elhendawy Stefan Zeuzem Albrecht Piiper Oliver Waidmann | 2013 | European Journal of Cancer2013，，： | 2 |
| 10 | Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer 显示文摘 | Bode C Trojan L Weiss C | 2009 | Oncol Rep2009，22，2： | 1 |
| 11 | Minimally- invasivetherapyofurinarystones显示文摘 | KNOLL T TROJAN L HAECKER A | 2003 | Aktuelle Urol2003，34，： | 1 |
| 12 | Cystic adrenal lym phangioma: incidental diagnosis on abdominal sonography 显示文摘 | Trojan J Schwarz W Zeuzem S | 2000 | AJR2000，174，： | 1 |
| 13 | Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b显示文摘 | Erik H.C.J. Buster Hajo J. Flink Yilmaz Cakaloglu Krzysztof Simon J?rg Trojan Fehmi Tabak Thomas M.K. So S. Victor Feinman Tomasz Mach Ulus S. Akarca Martin Schutten Wanda Tielemans Anneke J. van Vuuren Bettina E. Hansen Harry L.A. Janssen | 2008 | Gastroenterology2008，，2： | 1 |
| 14 | New trends in ballistocardiography显示文摘 | Trefny Z Trojan S Toman V | 2003 | Measure Science Review2003，3，2： | 1 |
| 15 | Prognos- tic factors of papillary renal cell carcinoma:results from a multi-institutional series after pathological review 显示文摘 | Edwin Herrmann Lutz Trojan Frank Becket | 2010 | The Journal of Urology2010，183，： | 1 |
| 16 | Complications in per-cutaneous nephrolithotomy显示文摘 | Michel M S Trojan L Rassweiler J J | 2007 | Eur Urol2007，51，4： | 1 |
| 17 | Complications in percu- taneous nephrolithotomy显示文摘 | Michel MS Trojan L Rassweiler JJ | 2007 | Eur Urol2007，51，4： | 1 |
| 18 | Ba Sn1-xTbxO3:A new yellow pigment based on a perovskite structure显示文摘 | LUNAKOVA P TROJAN M LUXOVA J | 2013 | Dye Pigment2013，，96： | 1 |
| 19 | Cyclooxygenase-2 ( COX-2 ) is frequnently expressed in multiple myeloma and is an independent predictor of poor outcome 显示文摘 | Ladetto M Vallet S Trojan A | 2005 | Blood2005，105，12： | 1 |
| 20 | Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer 显示文摘 | Trojan A Urosevic M Dummer R | 2004 | Lung Cancer2004，44，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员